Results 111 to 120 of about 87,925 (315)
Hematology, 2017 Objectives: Imatinib, a breakpoint cluster region-Abelson murine leukemia tyrosine kinase inhibitor, has revolutionized the treatment of chronic myelogenous leukemia (CML).
Haiying Wang +7 more
semanticscholar +1 more source
BMJ Case Reports, 2018 Imatinib is a specific tyrosine kinase inhibitor which has been approved for the treatment of Philadelphia chromosome-positive chronic myeloid leukaemia and c-KIT (CD117)-positive gastrointestinal stromal tumours. It has been associated with hepatotoxicity ranging from abnormal liver function tests to acute liver failure along with chronic hepatitis B ...
Mohammad Inamul Haq +2 more
openaire +4 more sources
Pediatric Blood &Cancer, EarlyView.ABSTRACT The chronic nature of chronic myeloid leukemia (CML) has a negative impact on patients’ health‐related quality of life (HRQOL) and the need for prolonged oral tyrosine kinase inhibitors (TKIs) poses a risk to low or nonadherence over time. This systematic review seeks to analyze HRQOL outcomes and adherence to TKIs among pediatric, adolescent,
Rachel S. Werk +2 more
wiley +1 more source
Development and targeted use of nilotinib in chronic myeloid leukemia
Drug Design, Development and Therapy, 2008 Carmen Fava, Hagop Kantarjian, Jorge Cortes, Elias JabbourDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USAAbstract: The development of imatinib has resulted in sustained hematologic and cytogenetic remissions
Carmen Fava +3 more
doaj
LncRNA MEG3 Regulates Imatinib Resistance in Chronic Myeloid Leukemia via Suppressing MicroRNA-21
Biomolecules & Therapeutics, 2017 Imatinib resistance has become a major clinical problem for chronic myeloid leukemia. The aim of the present study was to investigate the involvement of MEG3, a lncRNA, in imatinib resistance and demonstrate its underlying mechanisms. RNAs were extracted
Xiangyu Zhou +3 more
semanticscholar +1 more source
The Journal of Experimental Medicine, 2008 Researchers have discovered a new a way to make the anticancer drug imatinib more effective. By suppressing the oncogene AHI-1, Zhou and colleagues were able to hold chronic myeloid leukemia (CML) in check (page 2657). Figure 1 A combination of imatinib and an AHI-1 blocker (red) killed more cells from imatinib-resistant CML patients ...
openaire +2 more sources
PROTEOMICS, EarlyView.ABSTRACT Posttranslational modifications (PTMs) are of significant interest in molecular biomedicine due to their crucial role in signal transduction across various cellular and organismal processes. Characterizing PTMs, distinguishing between functional and inert modifications, quantifying their occupancies, and understanding PTM crosstalk are ...
Payman Nickchi +5 more
wiley +1 more source
Current Problems in Cancer: Case ReportsIntroduction: Imatinib has led to a phenomenal progress in the treatment of GIST. A rare and lesser-known side effect of imatinib is pneumonitis, an uncommon multicausal interstitial lung disease.
Deborah van de Wal +11 more
doaj
Therapeutic Advances in HematologyBackground: Generics imatinib became an alternative treatment option for chronic myeloid leukemia (CML) patients in China. However, clinicians and patients alike harbor concerns regarding the long-term safety of generic imatinib.
Fang Cheng +5 more
doaj +1 more source
Journal of Experimental & Clinical Cancer Research, 2009 Background Imatinib, a tyrosine kinase inhibitor currently approved for treatment of several malignancies, has been shown to be a substrate for multiple efflux-transporter proteins, including ABCB1 (P-glycoprotein) and ABCG2 (BCRP).
Sparreboom Alex +3 more
doaj +1 more source